In­tel­lia dos­es first pa­tient with an­ti-HAE gene ther­a­py; So­bi an­nounces new R&D chief

Gene ther­a­py biotech In­tel­lia Ther­a­peu­tics has dosed its first pa­tient with genome edit­ing can­di­date NT­LA-2002, its drug can­di­date for hered­i­tary an­gioede­ma …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER